ZA961460B - Vaccine compositions - Google Patents

Vaccine compositions

Info

Publication number
ZA961460B
ZA961460B ZA961460A ZA961460A ZA961460B ZA 961460 B ZA961460 B ZA 961460B ZA 961460 A ZA961460 A ZA 961460A ZA 961460 A ZA961460 A ZA 961460A ZA 961460 B ZA961460 B ZA 961460B
Authority
ZA
South Africa
Prior art keywords
vaccine compositions
vaccine
compositions
Prior art date
Application number
ZA961460A
Other languages
English (en)
Inventor
Pierre Hauser
Nathalie Marie-Josephin Garcon
Pierre Desmons
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10770292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA961460(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of ZA961460B publication Critical patent/ZA961460B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA961460A 1995-02-25 1996-02-23 Vaccine compositions ZA961460B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9503863.4A GB9503863D0 (en) 1995-02-25 1995-02-25 Vaccine compositions

Publications (1)

Publication Number Publication Date
ZA961460B true ZA961460B (en) 1996-08-29

Family

ID=10770292

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA961460A ZA961460B (en) 1995-02-25 1996-02-23 Vaccine compositions

Country Status (35)

Country Link
US (1) US5972346A (de)
EP (1) EP0810877B1 (de)
JP (1) JP3881015B2 (de)
KR (1) KR100365373B1 (de)
CN (1) CN1101225C (de)
AP (1) AP766A (de)
AR (1) AR002279A1 (de)
AT (1) ATE209045T1 (de)
AU (1) AU695921B2 (de)
BG (1) BG101851A (de)
BR (1) BR9607458A (de)
CA (1) CA2212552C (de)
CZ (1) CZ288417B6 (de)
DE (1) DE69617211T2 (de)
DK (1) DK0810877T3 (de)
EA (1) EA199700126A1 (de)
ES (1) ES2166879T3 (de)
FI (1) FI118118B (de)
GB (1) GB9503863D0 (de)
HU (1) HU224832B1 (de)
IL (1) IL117249A (de)
MA (1) MA23814A1 (de)
MX (1) MX9706450A (de)
MY (1) MY113428A (de)
NO (1) NO319394B1 (de)
NZ (1) NZ302674A (de)
OA (1) OA10612A (de)
PL (1) PL182679B1 (de)
PT (1) PT810877E (de)
SA (1) SA96160633B1 (de)
SK (1) SK115097A3 (de)
TR (1) TR199700849T1 (de)
TW (1) TW467745B (de)
WO (1) WO1996026741A1 (de)
ZA (1) ZA961460B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620414B2 (en) * 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6488934B1 (en) * 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
US20010014331A1 (en) * 1996-11-07 2001-08-16 Smithkline Beecham Biologicals S.A. Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
US20030049268A1 (en) 1998-05-01 2003-03-13 Smithkline Beecham Biologicals S.A. Novel composition
GB9809507D0 (en) * 1998-05-01 1998-07-01 Smithkline Beecham Biolog Novel composition
PT1077722E (pt) 1998-05-22 2006-12-29 Coley Pharm Group Inc Produtos e composições para utilização na indução da imunidade mucosal
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
CA2355680A1 (en) * 1998-12-23 2000-06-29 Qinjian Zhao Improved recombinant hepatitis b surface antigen
DE60014076T2 (de) 1999-04-19 2005-10-13 Glaxosmithkline Biologicals S.A. Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
US20090214592A1 (en) * 2005-02-16 2009-08-27 O'hagan Derek Adjuvant composition comprising aluminium phosphate and 3D-MPL
ATE526036T1 (de) * 2005-08-02 2011-10-15 Novartis Vaccines & Diagnostic Reduzierung der interferenz zwischen ölhaltigen adjuvanzien und surfactanthaltigen antigenen
ES2420829T3 (es) 2005-11-04 2013-08-27 Novartis Vaccines And Diagnostics S.R.L. Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
EP1951298A1 (de) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Grippeimpfstoffe mit adjuvantien und zytokin-induzierenden mitteln
CN100415294C (zh) * 2005-12-23 2008-09-03 中国农业大学 一种治疗和/或预防乙肝的药物
EP3753574A1 (de) 2006-01-27 2020-12-23 Seqirus UK Limited Influenzaimpfstoffe mit hämagglutinin und matrixproteinen
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2004226A1 (de) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Lagerung von grippeimpfstoffen ohne kühlung
EP1862176A1 (de) * 2006-05-31 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
EP1862177A1 (de) * 2006-06-01 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
ES2536401T3 (es) 2006-09-11 2015-05-25 Novartis Ag Fabricación de vacunas contra virus de la gripe sin usar huevos
SG177141A1 (en) 2006-12-06 2012-01-30 Novartis Ag Vaccines including antigen from four strains of influenza virus
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2008339631B2 (en) 2007-12-24 2014-07-24 Novartis Ag Assays for adsorbed influenza vaccines
EP4218799A1 (de) 2009-07-15 2023-08-02 GlaxoSmithKline Biologicals S.A. Rsv-f-proteinzusammensetzungen und verfahren zur herstellung davon
AU2012211278B2 (en) 2011-01-26 2016-11-10 Glaxosmithkline Biologicals Sa RSV immunization regimen
US9452212B2 (en) 2011-04-14 2016-09-27 Dynavax Technologies Corporation Methods and compositions for eliciting an immune response against hepatitis B virus
DK2707385T3 (da) 2011-05-13 2017-11-20 Glaxosmithkline Biologicals Sa RSV-F-præfusionsantigener
HK1254344A1 (zh) 2015-06-26 2019-07-19 Seqirus UK Limited 抗原匹配的流感疫苗
CN118987191A (zh) 2018-11-13 2024-11-22 变异生物技术公司 用于治疗乙型肝炎的免疫原性组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0414374T3 (da) * 1989-07-25 1998-03-09 Smithkline Beecham Biolog Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf
WO1992021292A2 (en) * 1991-05-29 1992-12-10 Origin Medsystems, Inc. Retraction apparatus and methods for endoscopic surgery
MA22842A1 (fr) * 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
FI945483A7 (fi) * 1992-05-23 1995-01-20 Smithkline Beecham Biologicals S A Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita
ATE157882T1 (de) * 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
GB9311536D0 (en) * 1993-06-04 1993-07-21 Unilever Plc Hot soluble low density extractable food product

Also Published As

Publication number Publication date
WO1996026741A1 (en) 1996-09-06
ATE209045T1 (de) 2001-12-15
NZ302674A (en) 1999-01-28
CZ288417B6 (en) 2001-06-13
CN1101225C (zh) 2003-02-12
CZ267497A3 (cs) 1998-02-18
BR9607458A (pt) 1998-06-30
PL182679B1 (pl) 2002-02-28
MY113428A (en) 2002-02-28
AU4878096A (en) 1996-09-18
NO319394B1 (no) 2005-08-08
JPH11501018A (ja) 1999-01-26
TW467745B (en) 2001-12-11
US5972346A (en) 1999-10-26
HU224832B1 (en) 2006-03-28
BG101851A (en) 1998-04-30
SA96160633B1 (ar) 2005-10-15
IL117249A (en) 2000-11-21
HUP9801242A3 (en) 2000-08-28
FI973457A0 (fi) 1997-08-22
HK1004117A1 (en) 1998-11-20
PL321966A1 (en) 1998-01-05
KR19980702480A (ko) 1998-07-15
AP766A (en) 1999-09-17
CA2212552C (en) 2006-07-11
NO973873L (no) 1997-08-22
OA10612A (en) 2002-08-29
TR199700849T1 (xx) 1998-01-21
JP3881015B2 (ja) 2007-02-14
MX9706450A (es) 1998-07-31
DE69617211T2 (de) 2002-07-25
AU695921B2 (en) 1998-08-27
CA2212552A1 (en) 1996-09-06
FI118118B (fi) 2007-07-13
EP0810877A1 (de) 1997-12-10
EP0810877B1 (de) 2001-11-21
IL117249A0 (en) 1996-06-18
AR002279A1 (es) 1998-03-11
GB9503863D0 (en) 1995-04-19
DE69617211D1 (en) 2002-01-03
FI973457L (fi) 1997-08-22
DK0810877T3 (da) 2002-02-25
AP9701060A0 (en) 1997-10-31
MA23814A1 (fr) 1996-10-01
SK115097A3 (en) 1998-02-04
PT810877E (pt) 2002-04-29
KR100365373B1 (ko) 2003-07-07
ES2166879T3 (es) 2002-05-01
NO973873D0 (no) 1997-08-22
HUP9801242A1 (hu) 1998-08-28
CN1176604A (zh) 1998-03-18
EA199700126A1 (ru) 1998-02-26

Similar Documents

Publication Publication Date Title
IL118004A0 (en) Vaccine compositions
ZA961460B (en) Vaccine compositions
EG20993A (en) Cleasing compositions
EG20989A (en) Cleasing compositions
IL109056A0 (en) Vaccine compositions
GB9613043D0 (en) Improved compositions
GB9500577D0 (en) Compositions
GB9511366D0 (en) Novel formulations
HU9600207D0 (en) Vaccine compositions
GB9504996D0 (en) Compositions
GB9516371D0 (en) Compositions
GB9326425D0 (en) Vaccine compositions
ZA961514B (en) Novel compositions
HUP9601550A2 (en) Particulale compositions
GB9515805D0 (en) Compositions
GB9510719D0 (en) Novel compositions
GB9614618D0 (en) Vaccine compositions
GB9508785D0 (en) Novel compositions
GB9604856D0 (en) Compositions
GB9517113D0 (en) Novel compositions
GB9519109D0 (en) Compositions
GB9526433D0 (en) Vaccine component
GB9403417D0 (en) Vaccine compositions
GB9416097D0 (en) Vaccine compositions
GB9425980D0 (en) Vaccine compositions